When it rains, it pours. Instead of a slow slide, COVID-19 vaccine sales at Moderna (NASDAQ: MRNA) collapsed in the third quarter. 

Investors who were hoping for steady cash flows from this vaccine maker were deeply disappointed when it reported results on Thursday, Nov. 3, 2022. Is it time to cut and run, or are there better days ahead? Here's what you should know.

Moderna has been plowing COVID-vaccine profits into its development pipeline. This could set the company up with new revenue streams, but for now, this is still a one-product business. 

Continue reading

Source Fool.com